Proactive Management Strategies for Potential Gastrointestinal Adverse Reactions With Ceritinib in Patients With Advanced ALK-positive Non-Small-Cell Lung Cancer

Cancer Management and Research - New Zealand
doi 10.2147/cmar.s96471
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

Treating Patients With ALK-positive Non-Small Cell Lung Cancer: Latest Evidence and Management Strategy

Therapeutic Advances in Medical Oncology
Oncology
2015English

Ceritinib Plus Nivolumab in Patients With Advanced ALK-rearranged Non-Small-Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2020English

Successful Rechallenge With Ceritinib After Leukocytoclastic Vasculitis During Ceritinib Treatment for Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Protein

Oncotarget
Oncology
2018English

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Chemoradiotherapy Followed by Durvalumab in Patients With Unresectable Advanced Non‐small Cell Lung Cancer: Management of Adverse Events

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Management of Patients With Advanced Non-Small Cell Lung Cancer: Role of Gefitinib

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Circadian Function in Patients With Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy